Literature DB >> 15925232

Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics.

Xiuhua Hao1, Gang Cheng, Jin Sun, Meijuan Zou, Jie Yu, Shuang Zhang, Fude Cui.   

Abstract

A validated HPLC method was developed for the quantification of scutellarin in rat plasma using a liquid-liquid extraction and an ultraviolet detection. Chromatographic separation of scutellarin in plasma was performed on a C18 column, with a mobile phase of acetonitrile-water (23:77, v/v), adjusted to pH 2.5 with 1M phosphoric acid, and rutin was used as an internal standard. The calibration curve was linear over the range 0.1-100 microg/ml in rat plasma. The average extraction recoveries were 85.9+/-8.9, 71.0+/-4.6, 72.7+/-1.2% (n=3) at concentrations of 0.1, 2, 100 microg/ml, respectively, and the within-day and between-day precisions were less than 15%. After intravenous administration to rats over the doses range of 10-40 mg/kg, the plasma concentration-time curve of scutellarin was best conformed to three-compartment open model. The AUC of scutellarin was proportional to dose, and the systemic clearance (Cl), elimination half-life (t1/2beta) and apparent volume of distribution (Vc) were not significantly different among the three doses, suggestive of the linear pharmacokinetics characteristic of scutellarin after intravenous administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925232     DOI: 10.1016/j.jpba.2005.01.004

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

Review 1.  Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review.

Authors:  Jialiang Gao; Guang Chen; Haoqiang He; Chao Liu; Xingjiang Xiong; Jun Li; Jie Wang
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

2.  Formulation optimization of scutellarin-loaded HP-β-CD/chitosan nanoparticles using response surface methodology with Box-Behnken design.

Authors:  Shanshan Liu; Paul C Ho
Journal:  Asian J Pharm Sci       Date:  2017-04-21       Impact factor: 6.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.